ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
AzurRx BioPharma Inc

AzurRx BioPharma Inc (AZRX)

3.45
0.00
(0.00%)
Al cierre: 06 Enero 3:00PM
3.45
0.00
( 0.00% )
Fuera de horario: -

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
3.45
Postura de Compra
3.41
Postura de Venta
3.51
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
Precio Anterior
3.45
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
13,500,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.48
Beneficio por acción (BPA)
-1.19
turnover
-
Beneficio neto
-16.1M

Acerca de AzurRx BioPharma Inc

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Dover, Delaware, USA
Fundado
-

AZRX Últimas noticias

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI” Three IBD clinical indications, including ulcerative colitis and Crohn’s disease, added to...

AzurRx BioPharma Announces Reverse Stock Split

BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the...

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic...

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned Part 2 of RESERVOIR Trial to Enroll Up to 150 Patients to Evaluate Efficacy of FW-1022...

AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted...

AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpointsStudy data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary...

AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819

BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted...

AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

AZRX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de AzurRx BioPharma?
El precio actual de las acciones de AzurRx BioPharma es US$ 3.45
¿Cuántas acciones de AzurRx BioPharma están en circulación?
AzurRx BioPharma tiene 13,500,000 acciones en circulación
¿Cuál es la capitalización de mercado de AzurRx BioPharma?
La capitalización de mercado de AzurRx BioPharma es USD 46.58M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de AzurRx BioPharma?
AzurRx BioPharma ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de AzurRx BioPharma?
El ratio precio/beneficio de AzurRx BioPharma es -2.48
¿Cuál es la moneda de reporte de AzurRx BioPharma?
AzurRx BioPharma presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de AzurRx BioPharma?
El último beneficio anual de AzurRx BioPharma es USD -16.1M
¿Cuál es la dirección registrada de AzurRx BioPharma?
La dirección registrada de AzurRx BioPharma es 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
¿Cuál es la dirección del sitio web de AzurRx BioPharma?
La dirección del sitio web de AzurRx BioPharma es www.enterothera.com
¿En qué sector industrial opera AzurRx BioPharma?
AzurRx BioPharma opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MSAIMultiSensor AI Holdings Inc
US$ 2.765
(38.25%)
2.47M
MCVTMill City Ventures III Ltd
US$ 3.06
(35.40%)
58.27k
QRTEBQurate Retail Inc
US$ 3.13
(22.27%)
103
NARIInari Medical Inc
US$ 78.80
(21.23%)
4.69M
XTIAXTI Aerospace Inc
US$ 0.1021
(16.02%)
351.58M
ENVBEnveric Biosciences Inc
US$ 0.3501
(-17.14%)
320.83k
AMSTAmesite Inc
US$ 3.38
(-16.54%)
59.83k
GDTCCytoMed Therapeutics Ltd
US$ 2.90
(-15.45%)
61.49k
SLRNACELYRIN Inc
US$ 2.98
(-14.61%)
499.8k
ACXPAcurx Pharmaceuticals Inc
US$ 0.9599
(-11.94%)
163.31k
XTIAXTI Aerospace Inc
US$ 0.1021
(16.02%)
351.58M
SVMHSRIVARU Holding Ltd
US$ 0.0519
(12.10%)
29.26M
CRKNCrown Electrokinetics Corporation
US$ 0.143
(7.52%)
24.61M
CDTConduit Pharmaceuticals Inc
US$ 0.0829
(14.66%)
16.57M
CEROCERo Therapeutics Holdings Inc
US$ 0.0469
(10.87%)
16.42M
nunaka nunaka 2 minutos hace
Why don't you just repost that information from a credible source if it is, infact a fact?
RDGL
oldman69 oldman69 2 minutos hace
This time it will keep going to $10 bucks and beyond!!!
Hell yeah!!!
IQST
Schrodingers Cat Schrodingers Cat 3 minutos hace
Jan 6 short volumes: CODX 32%, FLGT 34%, QDEL 52%, VERU 42%.
CODX VERU
Jimmy Joe Jimmy Joe 3 minutos hace
You are SO FOS!

Same old tired list of things that are mostly lies!

Keep going shyster!

Spin those lies.

Name calling, personal attack, and calling someone a liar when you have already been outed as a liar.
You've never been right 1
DBMM
100lbStriper 100lbStriper 5 minutos hace
Netlist, Inc. v. SAMSUNG ELECTRONICS CO., LTD. (2:21-cv-00463)
District Court, E.D. Texas
https://www.courtlistener.com/docket/61631188/netlist-inc-v-samsung-electronics-co-ltd/?filed_after=&filed_before=&entry_gte=&entry_lte=&order_by=desc

658

Jan 6, 20
NLST
norisknorewards norisknorewards 5 minutos hace
whats your interest here? they're going under, isn't that the plan anyways?
NWBO
willpellel willpellel 5 minutos hace
You seem to have your mind made up on the legitimacy of this stock............so why "watch to see". Why waist your time to see if your right?

Could it be 'your saying we may have a chance"
PSRU
RickNagra RickNagra 6 minutos hace
I am assuming the RSI reset today. It was probably getting too high and overheating the system. Anyone know the new RSI ?
FNMA
swingingRichard swingingRichard 6 minutos hace
How come Benny's $1000/hr lawyers can't find any of these "bashers?" How come no MM has been sued? What can one do to move up Benny's basher list? Maybe it's time to double down on the lithium dose. Maybe you should talk to your dr about Thorazine. 
AABB
canthelpit canthelpit 7 minutos hace
GTCH PORCH ,,, out of ammo for the time being on this one ,,,holding out for acouple of my other plays ,,,
GTCH
jimr1717 jimr1717 7 minutos hace
What happened to these deal announcements?

https://www.otcmarkets.com/stock/RAKR/news/Rainmaker-Worldwide-Signs-Water-as-a-Service-Agreement-with-Jamaicas-Northern-Caribbean-University?id=265606

And this one ....

https://www.otcmarkets.com/stock/RAKR/news
RAKR
oldman69 oldman69 7 minutos hace
Good to here from $5 00 bucks and beyond. Chas you may have to change that to $10 bucks and beyond!!!
HELL YEAH!!!
IQST
La Flaca La Flaca 7 minutos hace
I understand now. I too think they would have been better off by starting that confirmatory trial, and I guarantee you that they recognize that as well. It's too late unfortunately and hopefully Europe will approve. Do you agree that if Europe approves (big IF, I know), their chances of getting FDA
AVXL
freecs freecs 7 minutos hace
Surely you can understand the difference between proactive and reactive. Pumpers are proactive. Those that come to dispel their fables are merely reactive.

If there's no pumping and fables being told, there's no need to detract and poke holes in the balloon.
RDAR
powerbattles powerbattles 8 minutos hace
$CTOR News today stated they are evaluating strategic alternatives aimed at maximizing shareholder value through potential partnerships, joint ventures, mergers, acquisitions, and licensing.
CTOR
JoJr JoJr 9 minutos hace
Are you invested in RDAR?

And if so, are you saying that RDAR is a real company like you have a real skill set?

Unlike most penny stock P & D's... ?

If that's what you're saying, welcome aboard.
RDAR
redspinelpinktopaz redspinelpinktopaz 9 minutos hace
Is there anything organic about it?
LWLG
Stock Guy777 Stock Guy777 9 minutos hace
Who would've thought that they would take the horrible Louisiana news Over the weekend as positive publicity for the stock to raise as much as it did today. 
META
harry crumb harry crumb 10 minutos hace
1.00-1.25 possile by friday, watch an learn you Ai pumping pete's! Scams belong on the pinksheets, coming soon
ILLR
flipper44 flipper44 10 minutos hace
Correct.
NWBO
freecs freecs 10 minutos hace
What's coming?
RDAR
236T568 236T568 11 minutos hace
If you ever wondered what a spineless lowlife looked like, just review this short video

https://x.com/donwinslow/status/1876363463074975767
freecs freecs 11 minutos hace
I mean, you just proved my point.
RDAR
threewheeler threewheeler 11 minutos hace
dam that sux
FDCT
Investor2014 Investor2014 11 minutos hace
I don’t think Anavex will apply to the FDA for accelerated approval because the P2b/3 trial doesn’t include any accepted surrogate endpoints and there is no confirmatory trial initiated as is now a firm requirement, but I do think they should have initiated that confirmatory trial they said they wou
AVXL

Su Consulta Reciente

Delayed Upgrade Clock